How to accelerate the supply of vaccines to all populations worldwide?
This article reflects on lessons from the COVID-19 pandemic to accelerate global vaccine access, emphasizing regulatory agility, collaboration, and risk-based approaches. It compares challenges faced by early and later vaccine manufacturers, highlighting successes like reliance on trusted regulatory approvals, digital solutions, and streamlined processes. Post-pandemic shifts to rigid requirements, however, risked supply chain delays. The paper advocates sustaining flexible frameworks, harmonized standards, and global cooperation to ensure rapid response in future crises. Ideal for public health professionals, regulators, and industry stakeholders seeking insights into optimizing vaccine development and distribution.
Expanding Master Files for human medicinal products in the EU/EEA
CEPI and EFPIA collaborated to author a regulatory position paper on master files in the EU. A new “Pharmaceutical Master File” overarching model is proposed that encompasses existing master files procedures as well as expanded approaches not in place today. The flexible and modular Pharmaceutical Master File aims at enabling faster access to novel medicines, including vaccines.
Advancing local manufacturing capacities for vaccines within Africa – Opportunities, priorities and challenges
CEPI collaborated with ACDC and UCL to author this paper on advancing local manufacturing capacities and defining priority vaccines for Africa. It emphasizes the importance of preferential procurement and adequate regulatory systems, and it serves as a blueprint for policymakers, researchers, and manufacturers to enhance vaccine production capabilities. By focusing on regional priorities, this review aims to catalyst discussions and initiatives that will bridge significant gaps in vaccine accessibility across the African continent.
